BioSpace News Archive

Study will evaluate a percutaneous therapy designed to improve left ventricular function for patients with systolic heart failure

AtriCure, Inc. announced that it has entered into a definitive agreement to acquire SentreHEART, Inc., a privately held developer of percutaneous left atrial appendage management solutions.

Ascletis Pharma Inc. announces the opening of its Clinical Development Shanghai Center, signalling the further expansion of R&D capability, especially in Oncology and Non-alcoholic steatohepatitis.

Trial is to Assess Pharmacokinetics, Pharmacodynamics and Safety of the Oral Administration of MNK-6106 in Patients with HE

The dividend will be paid on September 20, 2019 to stockholders of record as of September 3, 2019.

It is the only approved and commercially available melphalan product in China.

Advanced AKR-001 into Phase 2a BALANCED clinical study in NASH

The union of both products supports a seamless workflow with uninterrupted patient surface tracking and monitoring from setup through treatment.

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended June 30, 2019.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the Company has initiated patient recruitment for its upcoming pivotal cellulite trial across all four trial sites.